{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:25:46Z","timestamp":1779110746462,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00108-021-01248-x","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T16:05:15Z","timestamp":1642176315000},"page":"135-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Biologikatherapie von rheumatoider Arthritis und Spondyloarthritiden","Treatment of rheumatoid arthritis and spondylarthritis with biologics"],"prefix":"10.1007","volume":"63","author":[{"given":"Christoph","family":"Fiehn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,14]]},"reference":[{"key":"1248_CR1","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","volume":"389","author":"IB McInnes","year":"2017","unstructured":"McInnes\u00a0IB, Schett\u00a0G (2017) Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 389:2328\u20132337","journal-title":"Lancet"},{"issue":"7","key":"1248_CR2","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm.3260","volume":"19","author":"G Schett","year":"2013","unstructured":"Schett\u00a0G, Elewaut\u00a0D, McInnes\u00a0IB et al (2013) Toward a\u00a0cytokine-based disease taxonomy. Nat Med 19(7):822\u2013824","journal-title":"Nat Med"},{"key":"1248_CR3","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","volume":"389","author":"G Burmester","year":"2017","unstructured":"Burmester\u00a0G, Pope\u00a0JE (2017) Targeted treatments for rheumatoid arthritis 2. Novel treatment strategies in rheumatoid arthritis. Lancet 389:2338\u20132348","journal-title":"Lancet"},{"key":"1248_CR4","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1055\/a-1334-7609","volume":"146","author":"K Albrecht","year":"2021","unstructured":"Albrecht\u00a0K, Strangfeld\u00a0A (2021) Risikoprofil rheumatologische Basistherapie \u2013 ein Update aus dem RABBIT-Register. Dtsch Med Wochenschr 146:998\u20131002","journal-title":"Dtsch Med Wochenschr"},{"issue":"Suppl 2","key":"1248_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00393-018-0481-y","volume":"77","author":"C Fiehn","year":"2018","unstructured":"Fiehn\u00a0C, Holle\u00a0J, Iking-Konert\u00a0C et al (2018) S2e-Leitlinie: Behandlung der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten. Z\u00a0Rheumatol 77(Suppl 2):35\u201353","journal-title":"Z Rheumatol"},{"key":"1248_CR6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen\u00a0JS, Landew\u00e9\u00a0RBM, Bijlsma\u00a0JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699","journal-title":"Ann Rheum Dis"},{"key":"1248_CR7","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1136\/annrheumdis-2019-215304","volume":"78","author":"MM Verhoeven","year":"2019","unstructured":"Verhoeven\u00a0MM, de Hair\u00a0MJH, Janneke Tekstra\u00a0J (2019) Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U\u2011Act-Early and CAMERA-II treat-to-target trials. Ann Rheum Dis 78:1333\u20131338","journal-title":"Ann Rheum Dis"},{"key":"1248_CR8","first-page":"700","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec\u00a0L, Baraliakos\u00a0X, Kerschbaumer\u00a0A et\u00a0al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79:700\u2013712","journal-title":"Ann Rheum Dis"},{"issue":"supplement 1","key":"1248_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/annrheumdis-2021-eular.4091","volume":"80","author":"LC Coates","year":"2021","unstructured":"Coates\u00a0LC, Soriano\u00a0E, Corp\u00a0N et\u00a0al (2021) The group for research an assessment of psoriasis and psoriatic arthritis (GRAPPA) treatment recommendations 2021. Ann Rheum Dis 80(supplement 1):139","journal-title":"Ann Rheum Dis"},{"key":"1248_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00393-019-00709-x","volume":"79","author":"M K\u00f6hm","year":"2020","unstructured":"K\u00f6hm\u00a0M, Behrens\u00a0F (2020) Therapie der Psoriasisarthritis. Gibt es eine Differenzialindikation? Z\u00a0Rheumatol 79:23\u201332","journal-title":"Z Rheumatol"},{"key":"1248_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00393-016-0232-x","volume":"76","author":"U Kiltz","year":"2017","unstructured":"Kiltz\u00a0U, Rudwaleit\u00a0M, Sieper\u00a0J et al (2017) Evidenz-basierte Empfehlungen zur Diagnose und Therapie der axialen Spondyloarthritis: S3 Leitlinien der Deutschen Gesellschaft f\u00fcr Rheumatologie (DGRh) in Kooperation mit der Arbeitsgemeinschaft der medizinsich-wissenschaftlichen Fachgesellschaften (AWMF). Z\u00a0Rheumatol 76:111\u2013117","journal-title":"Z Rheumatol"},{"key":"1248_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","volume":"29","author":"ST Sarah","year":"2015","unstructured":"Sarah\u00a0ST, Nabeel\u00a0B, Nashla\u00a0B (2015) Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs 29:241\u2013258","journal-title":"BioDrugs"},{"key":"1248_CR13","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","volume":"74","author":"GR Burmester","year":"2015","unstructured":"Burmester\u00a0GR, Kivitz\u00a0AJ, Kupper\u00a0H et\u00a0al (2015) Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 74:1037\u20131044","journal-title":"Ann Rheum Dis"},{"key":"1248_CR14","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","volume":"381","author":"C Gabay","year":"2013","unstructured":"Gabay\u00a0C, Emery\u00a0P, Van Vollenhoven\u00a0R et al (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a\u00a0randomised, double-blind, controlled phase 4 trial. Lancet 381:1541\u20131550","journal-title":"Lancet"},{"key":"1248_CR15","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester\u00a0GR, Lin\u00a0Y, Patel\u00a0R et al (2017) Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a\u00a0randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 76:840\u2013847","journal-title":"Ann Rheum Dis"},{"key":"1248_CR16","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1136\/ard.2011.151043","volume":"70","author":"A Strangfeld","year":"2011","unstructured":"Strangfeld\u00a0A, Eveslage\u00a0M, Schneider\u00a0M et al (2011) Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70:1914\u20131920","journal-title":"Ann Rheum Dis"},{"key":"1248_CR17","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1136\/annrheumdis-2015-207838","volume":"75","author":"A Richter","year":"2016","unstructured":"Richter\u00a0A, Listing\u00a0J, Schneider\u00a0M et\u00a0al (2016) Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis. Ann Rheum Dis 75:1667\u20131673","journal-title":"Ann Rheum Dis"},{"key":"1248_CR18","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1136\/annrheumdis-2013-203341","volume":"73","author":"A Zink","year":"2014","unstructured":"Zink\u00a0A, Manger\u00a0B, Kaufmann\u00a0J (2014) Validation of the RABBIT risk score for serious infections. Ann Rheum Dis 73:1673\u20131676","journal-title":"Ann Rheum Dis"},{"key":"1248_CR19","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/ard.2009.118935","volume":"69","author":"WG Dixon","year":"2010","unstructured":"Dixon\u00a0WG, Hyrich\u00a0KL, Watson\u00a0KD et al (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69:522\u2013528","journal-title":"Ann Rheum Dis"},{"key":"1248_CR20","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","volume":"76","author":"A Strangfeld","year":"2017","unstructured":"Strangfeld\u00a0A, Richter\u00a0A, Siegmund\u00a0B et\u00a0al (2017) Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis 76:504\u2013510","journal-title":"Ann Rheum Dis"},{"key":"1248_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001896","author":"AC Regierer","year":"2021","unstructured":"Regierer AC, Hasseli R, Sch\u00e4fer M et al (2021) TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV\u20112 infection in patients with RMD. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2021-001896","journal-title":"RMD Open"},{"key":"1248_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/acr.23875","volume":"72","author":"S Singh","year":"2020","unstructured":"Singh\u00a0S, Fumery\u00a0M, Singh\u00a0AG et al (2020) Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 72:561\u2013576","journal-title":"Arthritis Care Res"},{"key":"1248_CR23","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2017-211209","volume":"76","author":"Y Meissner","year":"2017","unstructured":"Meissner\u00a0Y, Richter\u00a0A, Manger\u00a0B et\u00a0al (2017) Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort. Ann Rheum Dis 76:1583\u20131590","journal-title":"Ann Rheum Dis"},{"key":"1248_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/annrheumdis-2020-eular.1505","volume":"79","author":"M Sch\u00e4fer","year":"2020","unstructured":"Sch\u00e4fer\u00a0M, Schneider\u00a0M, Grae\u00dfler\u00a0A et al (2020) TNF inhibitors are associated with a\u00a0reduced risk of venous thromboembolism compared to csDMARDs in RA patients. EULAR E\u2011Congress. Ann Rheum Dis 79:8\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.1505","journal-title":"Ann Rheum Dis"},{"key":"1248_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","volume":"76","author":"LK Mercer","year":"2017","unstructured":"Mercer\u00a0LK, Askling\u00a0J, Raaschou\u00a0P et\u00a0al (2017) Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a\u00a0collaborative project of 11 European biologic registers. Ann Rheum Dis 76:386\u2013391","journal-title":"Ann Rheum Dis"},{"key":"1248_CR26","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1136\/annrheumdis-2017-211623","volume":"76","author":"LK Mercer","year":"2017","unstructured":"Mercer\u00a0LK, Regierer\u00a0AC, Mariette\u00a0X et\u00a0al (2017) Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a\u00a0European registries collaborative project. Ann Rheum Dis 76:2025\u20132030","journal-title":"Ann Rheum Dis"},{"key":"1248_CR27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/BOR.0000000000000492","volume":"30","author":"AC Regierer","year":"2018","unstructured":"Regierer\u00a0AC, Strangfeld\u00a0A (2018) Rheumatoid arthritis treatment in patients with a\u00a0history of cancer. Curr Opin Rheumatol 30:288\u2013294","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"1248_CR28","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/acr.20155","volume":"62","author":"LC Coates","year":"2010","unstructured":"Coates\u00a0LC, Helliwell\u00a0PS (2010) Validation of minimal disease activity criteria for psoriatric arthritis using interventional trial data. Arthritis Care Res 62(7):965\u2013969","journal-title":"Arthritis Care Res"},{"issue":"Suppl 2","key":"1248_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00393-019-0680-1","volume":"78","author":"K Albrecht","year":"2019","unstructured":"Albrecht\u00a0K, Callhoff\u00a0J, Zink\u00a0A (2019) Langzeittrends in der rheumatologischen Versorgung. Erfolge und Defizite im Spiegel von 25\u00a0Jahren rheumatologischer Kerndokumentation. Z\u00a0Rheumatol 78(Suppl 2):65\u201372","journal-title":"Z Rheumatol"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01248-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-021-01248-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01248-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T11:06:38Z","timestamp":1643886398000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-021-01248-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,14]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1248"],"URL":"https:\/\/doi.org\/10.1007\/s00108-021-01248-x","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,14]]},"assertion":[{"value":"16 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Fiehn gibt an, dass folgende Interessenkonflikte bestehen: Referenten- oder Beraterhonorare von: Abbvie, AstraZeneca, BMS, Celgene, Celltrion, Galapagos, Janssen, Lilly, MSD, Medac, Novartis, Pfizer, Roche, Sanofi, UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}